ARG1 and neoplasm: The pharmaceutical targeting of MDSC end products iNOS or arginase 1, or systemic treatment with a phosphodiesterase V (PDE5) inhibitor, suppressed MDSC accumulation and function in HCC, reinstating an important role for NK cells in anti-tumor immunity [204].